Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company announced a merger between a SPAC and a Scilex subsidiary that is developing a non-opioid novel injectable corticosteroid, which will set up a spinoff of the combined entity in early 2025.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company announced a merger between a SPAC and a Scilex subsidiary that is developing a non-opioid novel injectable corticosteroid, which will set up a spinoff of the combined entity in early 2025.

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company released its 2Q2024 results that showed revenues that bested estimates as sales of its primary products showed robust growth, while adding another product to its mix.

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company recently added to its important line on non-opioid drugs by announcing the FDA approved the commercial manufacturing of Gloperba and that the product is being stocked in many national pharmacy chains and independent pharmacies.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company recently added to its important line on non-opioid drugs by announcing the FDA approved the commercial manufacturing of Gloperba and that the product is being stocked in many national pharmacy chains and independent pharmacies.

SCLX:  Product Gets FDA Approval and Hits Market

<ul><li>SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products.</li><li> The company already has commercialized products that are proven to improve patients' lives.</li><li> The company reported 1Q2024 results that were a little shy of estimates, but growth continues, and the product line should accelerate growth in the coming years.</li></ul>

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has commercialized products that are proven to improve patients' lives. The company reported 1Q2024 results that were a little shy of estimates, but growth continues, and the product line should accelerate growth in the coming years.

SCLX:  Making Decisions That Should Boost Revenue

United States

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido® for postherpetic neuralgia, ELYXYB® for migraine, and GLOPERBA® for gout flares. The company is headquartered in Palo Alto, California, and was founded in 2019.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Scilex (SCLX US)

SCLX: Company Sets up Spinoff

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Revenues Beat Estimates in 2Q

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Product Gets FDA Approval and Hits Market

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Making Decisions That Should Boost Revenue

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

SCLX: Making Decisions That Should Boost Revenue

SCLX is filling a much-needed area of the health care sector, that of developing non-opioid pain relief products. The company already has...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)